The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Article in Leukemia (July 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study
Article in Trials (September 2022)
Chronisch-entzündliche Darmerkrankungen in der COVID-Pandemie: Manifestationen und Management
Article in Zeitschrift für Gastroenterologie (February 2022)